BioCardia, Inc. (BCDA)
BCDANASDAQ-CMBiotechnology: Biological Products (No Diagnostic Substances)
$0.9026
+0.0746 (+9.01%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $13.66m
- P/E
- –
- EPS, last 4 quarters
- $-0.6400
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.7500 to $1.80
- Average volume
- 216.9k
- Previous close
- $0.8280
Analysts
1 coveringBuy1 buy, 0 hold, 0 sell
Targets a year out average $25.00, +2669.8% from here
Earnings
next estimate $-0.1500Next report Nov 11, 2026
Sep 2025
+4.0%
Dec 2025
+70.0%
Mar 2026
-23.5%
Jun 2026
+31.6%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$1.49m | -$2.01m | -$2.27m | -$1.62m |
| Net income | -$1.48m | -$1.98m | -$2.26m | -$1.61m |
News
8 latest- BioCardia, Inc. Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy SystemFintel · 4 days ago
- BioCardia Advances Helix Catheter Toward FDA Marketing Clearance RTTNews · Oct 19, 2026
- BioCardia To Provide Update On CardiAMP HF II Study For HfrEF At HFSA Conference RTTNews · Oct 7, 2026
- BioCardia Files Revised FDA Submission For Helix Catheter; Premarket Stock Up RTTNews · Oct 2, 2026
- BioCardia Gains FDA Confirmation On Pre-Sub Meeting Outcome; Amendment By Q4 '26 RTTNews · Aug 24, 2026
- BioCardia (BCDA) Q2 2026 Earnings Call TranscriptThe Motley Fool · Aug 19, 2026
- BioCardia Raises $4.4 Mln In Financing; Stock Down RTTNews · Jun 8, 2026
- BioCardia: FDA Says CardiAMP HF II May PMA For Cell Therapy In Ischemic HFrEF; Stock Up RTTNews · Jun 5, 2026
The company
BioCardia, Inc., headquartered in Sunnyvale, California, is developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company's biotherapeutic platforms for the treatment of heart disease. BioCardia also acts as a biotherapeutic delivery partner supporting therapies for the treatment of heart failure, chronic myocardial ischemia, and acute myocardial infarction.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- biocardia.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.